Image

Global Hypercalcemia Treatment Market – Industry Trends and Forecast to 2030

Healthcare

Image

Global Hypercalcemia Treatment Market – Industry Trends and Forecast to 2030

  • Healthcare
  • Upcoming Report
  • Oct 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Hypercalcemia Treatment Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 13628.90 USD million
Diagram Market Size (Forecast Year) USD 33854.70 USD million
Diagram CAGR %

Global Hypercalcemia Treatment Market, By Drug Class (Bisphosphonates, Calcimimetic Agents, Calcitonin, Denusomab, Glucocorticoids, Pipeline Analysis), Distribution Channel (Direct Tenders, Retail), Application (Mild Hypercalcemia, Moderate Hypercalcemia, Severe Hypercalcemia), End-User (Hospitals, Clinics) - Industry Trends and Forecast to 2030.

 Hypercalcemia Treatment Market

Hypercalcemia Treatment Market Analysis and Size

The increase in the geriatric globally is escalating the growth of the hypercalcemia treatment market. Hypercalcemia refers to a condition when calcium levels within the body increases rise with the serum calcium level that is greater than 2.6 mmol/L. This condition results in various problems such as weak bones and kidney stones. The treatment includes drugs or surgical removal of the overactive glands. To the access level of blood calcium, blood tests are also being done.  The rise in the number of cancer patients across the globe acts as one of the major factors driving the growth of hypercalcemia treatment market. The increase in the number of incidences of hypercalcemia among the population and the advent of new technology for the treatment for treating the disease accelerate the market growth.

Data Bridge Market Research analyses that the hypercalcemia treatment market which was USD 13,628.90 million in 2022, is expected to reach up to USD 33,854.70 million by 2030, and is expected to undergo a CAGR of 9.5% during the forecast period. This indicates that the market value. “Bisphosphonates” dominates the drug class segment of the global hypercalcemia treatment market owing to the rising incidences of cancer and other related issues. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Hypercalcemia Treatment Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Drug Class (Bisphosphonates, Calcimimetic Agents, Calcitonin, Denusomab, Glucocorticoids, Pipeline Analysis), Distribution Channel (Direct Tenders, Retail), Application (Mild Hypercalcemia, Moderate Hypercalcemia, Severe Hypercalcemia), End-User (Hospitals, Clinics)

Countries Covered

  • U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa

Market Players Covered

  • Fujirebio (Japan), DIASORIN S.p.A (Italy), Mylan N.V. (U.S.), Dr. Reddy’s Laboratories Ltd (India), Novartis AG (Switzerland), AbbVie Inc. (U.S.), Merck & Co., Inc. (U.S.), Amgen Inc. (U.S.), Sun Pharmaceutical Industries Ltd (U.S.), Kyowa Kirin Co. Ltd. (Japan), Cipla Inc. (India), Bayer AG (Switzerland), Pfizer Inc. (U.S.), OPKO Health, Inc. (U.S.), Rockwell Medical (U.S.), Mayo Foundation for Medical Education and Research (MFMER) (U.S.), Fortis Healthcare (India), sanofi-aventis U.S. LLC (France), Aetna Inc. (U.S.), AstraZeneca (U.K.), A6 Pharmaceuticals (U.S.), Johnson & Johnson Services, Inc. (U.S.)

Market Opportunities

  • Increasing awareness regarding hypercalcemia
  • Increasing technological advancements

Market Definition

The term "hypercalcemia treatment" refers to medical procedures and regimens intended to lower and restore normal blood calcium levels (hypercalcemia). A serum calcium level of more than 10.4 mg/dL is commonly considered to be hypercalcemia, a medical disorder marked by an excess of calcium ions in the blood. While relieving symptoms, the main objective of hypercalcemia treatment is to address the underlying cause of the excessive calcium levels.

Global Hypercalcemia Treatment Market Dynamics

Drivers

  • Increasing Prevalence of Hypercalcemia

Hypercalcemia is a medical condition characterized by elevated levels of calcium in the blood. The rising incidence of hypercalcemia due to various underlying medical conditions, such as primary hyperparathyroidism, cancer, and kidney disease, is a significant driver for the hypercalcemia treatment market.

  • Rising Geriatric Population

The global aging population is more susceptible to conditions such as hypercalcemia. As the elderly population grows, the demand for hypercalcemia treatment is likely to increase.

Opportunities

  • Increasing Awareness Regarding Hypercalcemia

Increasing awareness among healthcare professionals and patients about hypercalcemia and its treatment options can contribute to early diagnosis and treatment.

  • Increasing Technological Advancements

Improved diagnostic tools and techniques enable early detection of hypercalcemia, which can lead to early treatment and a higher demand for therapeutic options. Ongoing research and development efforts in the pharmaceutical industry are likely to lead to the introduction of new and more effective treatment options for hypercalcemia.

Restrains/Challenges

  • Strict Regulations and Guidelines

The approval and regulation of drugs for hypercalcemia treatment can be complex, as these drugs may also be used for other medical conditions. Navigating regulatory processes and obtaining approvals can be time-consuming and costly for pharmaceutical companies.

  • High Cost of Equipment

Depending on the underlying cause of hypercalcemia and the required treatment, the cost of managing the condition can be significant. This can be a barrier to access to treatment, particularly in regions with limited healthcare resources.

  • Limited Treatment Options

There were limited treatment options specifically approved for hypercalcemia. Bisphosphonates and calcimimetics were commonly used, but more targeted therapies for specific underlying causes were needed.

This hypercalcemia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hypercalcemia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Hypercalcemia Treatment Market Scope

The hypercalcemia treatment market is segmented on the basis of drug class, distribution channel, application, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Drug Class

  • Bisphosphonates
  • Calcimimetic Agents
  • Calcitonin
  • Denusomab
  • Glucocorticoids
  • Pipeline Analysis

Application

  • Mild Hypercalcemia
  • Moderate Hypercalcemia
  • Severe Hypercalcemia

End-Users

  • Hospitals
  • Clinics

Distribution Channel

  • Direct Tenders
  • Retail

Global Hypercalcemia Treatment Market Regional Analysis/Insights

The hypercalcemia treatment market is analyzed and market size insights and trends are provided by drug class, distribution channel, application, and end-user as referenced above.      

The countries covered in the hypercalcemia treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the hypercalcemia treatment market because of the increase in the prevalence of hyperthyroidism within the region. Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in its awareness in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.      

Competitive Landscape and Hypercalcemia Treatment Market Share Analysis

The hypercalcemia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related hypercalcemia treatment market.

Some of the major players operating in the hypercalcemia treatment market are:

  • Fujirebio (Japan)
  • DIASORIN S.p.A (Italy)
  • Mylan N.V. (U.S.)
  • Dr. Reddy’s Laboratories Ltd (India)
  • Novartis AG (Switzerland)
  • AbbVie Inc. (U.S.)
  • Merck & Co., Inc. (U.S.)
  • Amgen Inc. (U.S.)
  • Sun Pharmaceutical Industries Ltd (U.S.)
  • Kyowa Kirin Co. Ltd. (Japan)
  • Cipla Inc. (India)
  • Bayer AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • OPKO Health, Inc. (U.S.)
  • Rockwell Medical (U.S.)
  • Mayo Foundation for Medical Education and Research (MFMER) (U.S.)
  • Fortis Healthcare (India)
  • Sanofi-aventis U.S. LLC (France)
  • Aetna Inc. (U.S.)
  • AstraZeneca (U.K.)
  • A6 Pharmaceuticals (U.S.)
  • Johnson & Johnson Services, Inc. (U.S.) 


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Hypercalcemia Treatment Market will be worth USD 33,854.70 million by 2030.
The Hypercalcemia Treatment Market growth rate is 9.5% during the forecast period.
Increasing Prevalence of Hypercalcemia & Rising Geriatric Population are the growth drivers of the Hypercalcemia Treatment Market.
The drug class, distribution channel, application, and end-user are the factors on which the Hypercalcemia Treatment Market research is based.
Fujirebio (Japan), DIASORIN S.p.A (Italy), Mylan N.V. (U.S.), Dr. Reddy’s Laboratories Ltd (India), Novartis AG (Switzerland), AbbVie Inc. (U.S.), Merck & Co., Inc. (U.S.), Amgen Inc. (U.S.), Sun Pharmaceutical Industries Ltd (U.S.), Kyowa Kirin Co. Ltd. (Japan), Cipla Inc. (India), Bayer AG (Switzerland), Pfizer Inc. (U.S.), OPKO Health, Inc. (U.S.), Rockwell Medical (U.S.), Mayo Foundation for Medical Education and Research (MFMER) (U.S.), Fortis Healthcare are the major companies in the Hypercalcemia Treatment Market.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials